$SGHT

Sight Sciences, a medical technology company specializing in eye diseases, particularly glaucoma, is under investor focus following its recent earnings report and FDA updates. The company's revenue is driven by its glaucoma surgery platform, with growth influenced by procedure volumes, reimbursement trends, and surgeon adoption, while also investing in commercialization and R&D. While competition is intense, Sight Sciences positions itself through focused innovation and engagement with ophthalmic surgeons, making clinical data, competition, and healthcare policy key factors for investors to monitor.